1月14日，士泽生物宣布连续完成B/B+轮及C1轮四亿元市场化融资。其中，B/B+轮融资由三生制药领 投，泰珑/泰鲲资本及凯莱英医药集团联合领投，建发新兴投资、苏州天使母基金、七晟资本、信熹资 本、天汇资本等联合投资，峰瑞资本、启明创投、礼来亚洲基金、红杉中国等老股东持续追加投资； C1轮融资由国新基金领投，余姚工投跟投。 ...

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a strong increase, reaching a peak of 2.88% and currently up by 2.52% [1][4]. Group 1: ETF Performance - The ETF's price reached a high of 0.577, with a current price of 0.569, reflecting a gain of 0.014 or 2.52% [2][6]. - The trading volume for the ETF was reported at 178,084 shares, with a turnover rate of 3.73% [6]. Group 2: Component Stocks - Notable performers among the ETF's component stocks include China Biologic Products, BeiGene, and Hansoh Pharmaceutical, with respective increases of 5.21%, 3.53%, and 3.14% [1][5]. - Conversely, the stocks of Jiujiu Bio and Ascletis Pharma showed significant declines [1][5]. Group 3: Market Expectations - The JPM Healthcare Conference, held from January 12 to 15, 2026, has generated market anticipation regarding business development (BD) transaction data from Chinese innovative pharmaceutical companies, suggesting potential for increased international collaboration [6][7]. - The approval of updated labeling for the PD-1/VEGF dual antibody by the National Medical Products Administration for Kangfang Biopharma is expected to enhance treatment options for non-small cell lung cancer, indicating significant survival benefits [6][7]. Group 4: Industry Outlook - According to Western Securities, the innovative drug sector in Hong Kong is expected to maintain a structural market trend in 2026, with accelerated BD activities narrowing the price gap between Chinese and U.S. innovative drugs, leading to substantial long-term growth potential [7]. - Huafu Securities emphasizes that innovation will be a clear focus in 2026, particularly in cutting-edge technology platforms such as gene therapy and small nucleic acids [7].

Core Insights - The collaboration between AbbVie and Rongchang Biopharma marks a significant shift in the global oncology treatment landscape, highlighting the trend of "Chinese innovation + global market" in drug development [1][2] Group 1: Collaboration Details - AbbVie and Rongchang Biopharma signed an exclusive licensing agreement for the development, production, and commercialization of RC148, a bispecific antibody targeting PD-1 and VEGF [1] - Rongchang Biopharma will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in milestone payments, along with a tiered royalty on net sales outside Greater China [1][2] Group 2: Market Implications - The deal allows Rongchang Biopharma to accelerate clinical trials for RC148 in China and globally, while also supporting the development of other pipelines [2] - AbbVie aims to enhance its product portfolio in immuno-oncology, particularly in the emerging PD-1/VEGF bispecific antibody space, which could improve its competitiveness in solid tumor treatments [2] Group 3: Industry Trends - The PD-1/VEGF bispecific antibody represents a new class of cancer therapies that may overcome tumor resistance mechanisms by simultaneously blocking PD-1 and VEGF [3][5] - Chinese companies are leading in this field, with significant advancements and approvals, such as the launch of Ak112/Ivonescimab by Kangfang Biopharma, which is the first bispecific antibody combining tumor immunity and anti-angiogenesis mechanisms [3] Group 4: Broader Market Dynamics - The global interest in PD-1/VEGF bispecific antibodies is rising, with several Chinese firms successfully engaging in business development (BD) transactions, reflecting the increasing recognition of Chinese innovative drug assets by multinational pharmaceutical companies [6][7] - In 2025, the total value of Chinese innovative drug licensing transactions exceeded $130 billion, accounting for 49% of the global total, indicating a significant shift in the global pharmaceutical landscape [7][8] Group 5: Future Outlook - The increasing number of approved innovative drugs in China, along with the growing bargaining power of Chinese companies in licensing agreements, suggests a transition from a "follow" to a "lead" position in global pharmaceutical innovation [8][10] - The ability of Chinese companies to negotiate favorable terms in BD transactions is becoming crucial, emphasizing the importance of pipeline strength, data quality, and structured deal design [9][10]

Core Insights - The collaboration between AbbVie and Rongchang Biopharma marks a significant shift in the global oncology treatment landscape, focusing on the development of the bispecific antibody RC148 targeting PD-1 and VEGF [1][2] Group 1: Collaboration Details - AbbVie and Rongchang Biopharma signed an exclusive licensing agreement for RC148, granting AbbVie rights outside Greater China for development, production, and commercialization [1] - Rongchang Biopharma will receive an upfront payment of $650 million and is eligible for up to $4.95 billion in milestone payments, along with a tiered royalty on net sales outside Greater China [1][2] Group 2: Market Implications - This deal exemplifies the "China innovation + global market" model, providing Rongchang Biopharma with substantial cash flow to accelerate clinical trials for RC148 and support other pipeline developments [2] - The partnership with a top-tier oncology company like AbbVie enhances Rongchang Biopharma's brand and bargaining power in international markets, while AbbVie benefits from expanding its immuno-oncology product portfolio [2] Group 3: Bispecific Antibody Landscape - RC148 represents a new class of cancer therapies aimed at simultaneously blocking PD-1 and VEGF, potentially overcoming tumor resistance mechanisms [5] - The PD-1/VEGF bispecific antibody field is gaining traction, with several Chinese companies, including Kangfang Biopharma and Junshi Biosciences, making significant advancements and entering clinical trials [6][7] Group 4: Industry Trends - The Chinese innovative drug sector is experiencing a surge in licensing deals, with over $130 billion in total transaction value in 2025, surpassing the U.S. for the first time [10] - Factors driving this trend include the impending patent cliff for major drugs and declining R&D efficiency among multinational pharmaceutical companies, leading them to seek external innovations [10][11] Group 5: Future Outlook - The Chinese pharmaceutical industry is transitioning from a follower to a leader in innovation, with a clear direction for future development [14] - Companies are focusing on building a comprehensive value creation logic recognized by international partners, enhancing their negotiation power in licensing agreements [12][13]

Group 1 - The core viewpoint of the news highlights the performance of the TaiKang Medical Health Fund, which saw declines in its two share classes, with Class C down by 13.45% and Class A down by 13.02% in 2025 [2][3] - The top ten holdings of the TaiKang Medical Health Fund in the third quarter of 2025 included companies such as JingTai Holdings, Kanglong Chemical, Fangzhou Jianke, SanSheng Pharmaceutical, Zhaoyan New Drug, Jiuan Medical, Yirui Technology, Lingrui Pharmaceutical, Baipusais, and Bid Medical [2] - The fund manager, Fu Hongzhe, has a background as a senior researcher at China Europe Fund Management Co., and has been with TaiKang since July 2019, becoming the fund manager on March 8, 2022 [2]

Core Viewpoint - Rongchang Biologics has signed an exclusive licensing agreement with AbbVie for the dual-specific antibody drug RC148, valued at approximately $5.6 billion (about 39.06 billion RMB), marking a significant milestone in the company's business development efforts [1][3]. Group 1: Business Development Transactions - The agreement with AbbVie includes an upfront payment of $650 million (about 4.53 billion RMB) and potential milestone payments of up to $4.95 billion (about 34.53 billion RMB) based on development, regulatory, and commercialization achievements [3]. - This transaction is noted as the highest upfront payment recorded in the innovative drug sector for business development (BD) transactions at the start of the year [3]. - Since 2025, Rongchang Biologics has completed three BD transactions, including the recent agreement with AbbVie, indicating a strategic push for international expansion [5][6]. Group 2: Financial Performance - For the first three quarters of 2025, Rongchang Biologics reported revenue of approximately 1.72 billion RMB, a year-on-year increase of 42.27%, while the net loss narrowed to 551 million RMB [7]. - The company’s cash reserves reached 1.07 billion RMB by the end of Q3 2025, an increase from 743 million RMB and 763 million RMB at the end of 2023 and 2024, respectively [7]. - Despite the increase in cash reserves, the company still faces a high debt ratio of 61.18% as of Q3 2025, indicating ongoing financial pressure [7]. Group 3: Market Reaction - On January 13, following the announcement of the AbbVie deal, Rongchang Biologics' A-shares hit the daily limit, closing at a 20% increase, with a total trading volume of 2.369 billion RMB [2]. - The H-shares also experienced a significant rise, closing up 7.87% [2]. - The market's positive response reflects investor confidence in the potential of the RC148 drug and the strategic partnership with AbbVie [6][8].

Market Overview - The three major indices collectively adjusted, with the Shenzhen Component Index falling over 1% and the ChiNext Index dropping nearly 2%. The trading volume in the Shanghai and Shenzhen markets reached 3.65 trillion yuan, an increase of 49.6 billion yuan from the previous trading day [1][9]. - A-share market has shown strong performance since the beginning of the year, with abundant liquidity and record-high trading volumes. Investor optimism for the first half of 2026 is supported by frequent catalysts in the technology sector, including IPOs in AI and semiconductors, and innovations in AI applications [10]. Sector Performance - The pharmaceutical sector led the gains today, with the Innovation Drug ETF (517110) rising by 2.69% and the Biopharmaceutical ETF (512290) increasing by 1.57%. This is attributed to several overseas innovative drug collaborations and catalysts [13][14]. - AI healthcare is experiencing global catalysts, with OpenAI integrating health dialogue features into ChatGPT, enhancing user access to health data [14]. Gold Market Insights - Spot gold prices in London surpassed $4,600 per ounce, with Citigroup raising its 0-3 month target price to $5,000 per ounce. State Street indicated a greater than 30% chance of gold hitting this target this year [11]. - Geopolitical risks have increased, driving up gold's risk premium. The U.S. administration is discussing potential interventions in Iran, which could escalate conflicts in the Middle East [12][11]. Electricity and Infrastructure - The electricity sector showed relative strength, driven by the upcoming National Grid meetings and ongoing power supply issues in North America. The approval of high-voltage direct current projects has accelerated since mid-2025, indicating strong demand for electricity infrastructure [15][6]. - The global energy transition is creating a need for enhanced electricity grid construction to support renewable energy integration, particularly in underdeveloped regions [15]. Investment Recommendations - Investors are advised to consider the China Securities A500 ETF (159338) for broad exposure to leading companies across various sectors, and to adopt a "dumbbell" strategy focusing on technology and dividends to balance growth and volatility [10]. - For gold investments, options include direct investment in physical gold and gold ETFs that cover the entire industry chain [12]. Future Outlook - The market is expected to continue its upward trend due to ample liquidity and high demand in the AI sector. However, a potential phase of correction may occur following rapid market gains [10]. - The pharmaceutical sector's global competitiveness is strengthening, with upcoming earnings announcements from innovative drug companies anticipated to act as catalysts [14].

Core Viewpoint - The news highlights the strong performance of WuXi AppTec, with significant revenue and profit growth projections for 2025, driven by its integrated CRDMO business model and increasing demand for its services [3][4]. Group 1: Company Performance - WuXi AppTec expects to achieve approximately 454.56 billion yuan in revenue for 2025, representing a year-on-year growth of about 15.84%, with a 21.4% increase in revenue from continuing operations [3]. - The adjusted net profit attributable to shareholders is projected to be around 149.57 billion yuan, reflecting a year-on-year increase of approximately 41.33% [3]. - The company has revised its revenue guidance upwards, with total revenue expectations adjusted from 425-435 billion yuan to 435-440 billion yuan for 2025 [3]. Group 2: Market Trends - The Hang Seng Biotechnology ETF (513280) saw a 1.57% increase, with trading volume exceeding 1.4 billion yuan, indicating a significant uptick in market interest [1]. - WuXi AppTec's stock rose over 8%, outperforming many peers in the biotechnology sector, which also saw positive movements [4]. Group 3: Industry Insights - The AI healthcare application sector is rapidly advancing, with significant policy support and market demand driving commercialization [6]. - AI in drug development is expected to enhance early-stage research efficiency, significantly reducing the time required for drug candidate identification [6][7]. - The integration of AI in healthcare is becoming increasingly prevalent, with tools like ChatGPT Health facilitating better health information management for users [8][9].

Group 1 - The MSCI China Healthcare Index has increased by 11.8% year-to-date, outperforming the MSCI China Index which rose by 9.1% [1] - The pharmaceutical industry has seen significant growth, primarily due to the valuation correction that occurred in the fourth quarter of last year, leading to strong allocation interest from institutional investors at the beginning of the year [1] - The trend of innovative drugs going overseas is expected to continue until 2026, with a focus on the clinical progress and data validation of pipelines that have already entered international markets [1] Group 2 - The report recommends buying shares in companies such as 3SBio, Genscript Biotech, WuXi AppTec, and China National Pharmaceutical Group [1]

创新药迎来利好！ 另外，有报道指出，艾伯维是荣昌生物合作过的药企中市值最大的一家，根据美国《制药经理人》 （Pharm Exec）杂志公布的2025年度《全球制药企业50强》排行榜，艾伯维2024财年的处方药销售数据 高达544.84亿美元，在全球药企中排名第二，与第一名强生的差距仅约2%。 值得注意的是，昨天，中国创新药核心资产——二代IO疗法发生三件大事。一是荣昌生物重磅且超预 期BD落地；二是康方生物/Summit：AK112与美国BLA申报上市；三是三生制药/辉瑞：PF- 08634404/SSGJ-707将于2026年开展五项全球多中心Ⅲ期临床试验。有分析人士认为，二代IO赛道在全 球的竞争力值得看好。 根据荣昌生物公告，1月12日，公司与艾伯维集团控股公司（以下简称"艾伯维"）就RC148——一款新 型靶向PD-1/VEGF的双特异性抗体药物签署独家授权许可协议，本次交易总额最高为56亿美元（折合人 民币390亿元），首付款为6.5亿美元。 受此带动，今天创新药成为市场主角。荣昌生物A股20%涨停，港股创新药ETF上涨超3%。A股创新药 板块上涨超2.7%。诺思格（301333）、普蕊斯（3012 ...